Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma

Leukemia & Lymphoma
Theofanis EconomopoulosMeletios A Dimopoulos

Abstract

The majority of patients with indolent lymphomas relapse due to minimal residual disease (MRD). In the present study, we sought to determine whether by using rituximab consolidation, for eradication of MRD, following induction chemotherapy with fludarabine and mitoxantrone (FN) combination could improve the outcome of indolent lymphomas. Patients with indolent lymphoma received fludarabine 25 mg/m2 Day 1-3 and mitoxantrone 10 mg/m2 on Day 1 every 28 days. Patients who attained a response (complete response, CR or partial response, PR) received four weekly doses of Rituximab 375 mg/m2 1 month and 3 months after completion of treatment. Forty-five patients were entered into this Phase II trial. The median follow-up time was 39 months. The median number of delivered cycles was 6. Fifty-three percent of patients attained a CR and 38% a PR for an overall response rate of 91%. One patient had stable disease, one had progression of the disease, whereas 2 were non-evaluable. After a median follow-up of 39 months, 32 of 46 patients (74%) are alive and disease-free. Grade III and IV toxicities included leucopenia (37%), neutropenia (28%), thrombocytopenia (7%), anemia (4%), and diarrhea (2%). Grade V toxicities included septic death in o...Continue Reading

References

Feb 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T A Lister
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanC Varns
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Mar 9, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J Horning
May 16, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniS Tura
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A DavisR Levy
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F SeymourR M Fox
May 17, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Theofanis EconomopoulosMeletios Dimopoulos
May 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
Feb 15, 2005·The Oncologist·Fredrick HagemeisterPier Luigi Zinzani
Mar 26, 2005·The Veterinary Record·S A Headley
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael HeroldUNKNOWN East German Study Group Hematology and Oncology Study

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.